Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in Active Psoriatic Arthritis
NCT06807424Phase 3
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Countries
- 24
- Sponsor
- Janssen Pharmaceutical
- Modality
- Peptides
- Drugs
- icotrokinra
- Conditions
- psoriatic arthritis (PsA)
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 20 Response at 16 weeks. Started Jan 2025; status: active, not recruiting.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Group I: Icotrokinra Dose 1
Participants receive icotrokinra Dose 1.
Group II: Icotrokinra Dose 2
Participants receive icotrokinra Dose 2.
Group III: Placebo
Participants receive placebo matched to icotrokinra, crossing over to icotrokinra at Week 16.
03
Who it enrols
Participants must have active psoriatic arthritis despite previous use of a non-biologic DMARD, apremilast, or a biologic agent. They must also have active plaque psoriasis or nail changes consistent with psoriasis.
04
Endpoints
Primary
American College of Rheumatology 20 Response
Secondary
Psoriatic Area and Severity Index 75 Response
Psoriatic Area and Severity Index 90 Response
Psoriatic Area and Severity Index 100 Response
Investigator Global Assessment Psoriasis Score
American College of Rheumatology 50 Response
American College of Rheumatology 70 Response
Health Assessment Questionnaire-Disability Index
36 Item Short Form Survey Physical Component Summary
Beyond the preview
Go deeper on NCT06807424.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807424.